Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Farmers Insurance
Novartis
US Army
Dow
Covington
Mallinckrodt
US Department of Justice
Argus Health
Boehringer Ingelheim

Generated: August 16, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Galenic formulations of organic compounds
Abstract: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren, or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.
Inventor(s): Rigassi-Dietrich; Petra Gisela (Therwil, CH), Schmid; Martin (Wettingen, CH)
Assignee: Novartis AG (Basel, CH)
Filing Date:Jun 15, 2005
Application Number:11/153,728
Claims:1. A solid oral dosage form comprising a therapeutically effective amount of aliskiren free base, or a pharmaceutically acceptable salt thereof, and a carrier medium, wherein the oral dosage form exhibits an in vitro dissolution profile, when measured by the USP Basket Method at about 100 rpm in 500 mL of 0.01N HCI at about 37.degree. C., such that after 10 min, from a mean of about 27% to a mean of about 56% (by weight) of aliskiren free base, or a pharmaceutically acceptable salt thereof, is released, after 15 min, from a mean of about 41% to a mean of about 77% (by weight) of aliskiren free base, or a pharmaceutically acceptable salt thereof, is released, after 20 min, from a mean of about 53% to a mean of about 94% (by weight) of aliskiren free base, or a pharmaceutically acceptable salt thereof, is released, after 30 min, from a mean of about 74% to a mean of about 100% (by weight) of aliskiren free base, or a pharmaceutically acceptable salt thereof, is released, and after 45 min, from a mean of about 94% to a mean of about 100% (by weight) of aliskiren free base, or a pharmaceutically acceptable salt thereof, is released, wherein the solid oral dosage form also comprises the following excipients in an amount by weight per unit dosage form of 20-32% microcrystalline cellulose as filler, 3-4% PVP K 30 as binder, 13.5-15% crospovidone as disintegrant, 0.4-0.6% colloidal silicon dioxide as glidant, and 0.8-1.5% magnesium stearate as lubricant.

2. A solid oral dosage form according to claim 1, wherein aliskiren is in the form of a hemi-fumarate salt thereof, and a therapeutically effective amount ranges from about 83 to about 332 mg per unit dosage form.

3. A solid oral dosage form according to claim 2, wherein a therapeutically effective amount is about 83 mg per unit dosage form.

4. A solid oral dosage form according to claim 3, wherein the oral dosage form exhibits an in vitro dissolution profile such that after 10 min, a mean of about 55% of aliskiren hemi-fumarate, is released, after 15 min, a mean of about 77% of aliskiren hemi-fumarate, is released, after 20 min, a mean of about 92% of aliskiren hemi-fumarate, is released, after 30 min, a mean of about 94% of aliskiren hemi-fumarate, is released, and after 45 min, a mean of about 95% of aliskiren hemi-fumarate, is released wherein the solid oral dosage form also comprises the following excipients in an amount by mg per unit dosage form of about 53.6 mg microcrystalline cellulose as filler, about 6.0 mg PVP K 30 as binder, about 24.1 mg crospovidone as disintegrant, about 0.9 mg colloidal silicon dioxide as glidant, and about 2.5 mg magnesium stearate as lubricant.

5. A solid oral dosage form according to claim 1, wherein the dosage form further comprises a film-coating.

6. A solid oral dosage form according to claim 5, wherein aliskiren is in the form of a hemi-fumarate salt thereof, and a therapeutically effective amount ranges from about 83 to about 332 mg per unit dosage form.

7. A solid oral dosage form according to claim 6, wherein a therapeutically effective amount is about 83 mg per unit dosage form.

8. A solid oral dosage form according to claim 7, wherein the oral dosage form exhibits an in vitro dissolution profile such that after 10 min, a mean of about 53% of aliskiren hemi-fumarate, is released, after 15 min, a mean of about 76% of aliskiren hemi-fumarate, is released, after 20 min, to a mean of about 93% of aliskiren hemi-fumarate, is released, after 30 min, a mean of about 99% of aliskiren hemi-fumarate, is released, and after 45 min, a mean of about 99% of aliskiren hemi-fumarate, is released wherein the solid oral dosage form also comprises the following excipients in an amount by mg per unit dosage form of about 53.6 mg microcrystalline cellulose as filler, about 6.0 mg PVP K 30 as binder, about 24.1 mg crospovidone as disintegrant, about 0.9 mg colloidal silicon dioxide as glidant, and about 2.5 mg magnesium stearate as lubricant.

9. A solid oral dosage form according to claim 6, wherein a therapeutically effective amount is about 166 mg per unit dosage form.

10. A solid oral dosage form according to claim 9, wherein the oral dosage form exhibits an in vitro dissolution profile such that after 10 min, from a mean of about 32% to a mean of about 50% of aliskiren hemi-fumarate, is released, after 15 min, from a mean of about 50% to a mean of about 72% of aliskiren hemi-fumarate, is released, after 20 min, from a mean of about 67% to a mean of about 91% of aliskiren hemi-fumarate, is released, after 30 min, from a mean of about 95% to a mean of about 100% of aliskiren hemi-fumarate, is released, and after 45 min, from a mean of about 97% to a mean of about 100% of aliskiren hemi-fumarate, is released wherein the solid oral dosage form also comprises the following excipients in an amount by mg per unit dosage form of about 107 mg microcrystalline cellulose as filler, about 12.0 mg PVP K 30 as binder, about 48.2 mg crospovidone as disintegrant, about 1.8 mg colloidal silicon dioxide as glidant, and about 5.0 mg magnesium stearate as lubricant.

11. A solid oral dosage form according to claim 6, wherein a therapeutically effective amount is about 332 mg per unit dosage form.

12. A solid oral dosage form according to claim 11, wherein the oral dosage form exhibits an in vitro dissolution profile such that after 10 min, from a mean of about 27% to a mean of about 39% of aliskiren hemi-fumarate, is released, after 15 min, from a mean of about 41% to a mean of about 57% of aliskiren hemi-fumarate, is released, after 20 min, from a mean of about 53% to a mean of about 73% of aliskiren hemi-fumarate, is released, after 30 min, from a mean of about 74% to a mean of about 97% of aliskiren hemi-fumarate, is released, and after 45 min, from a mean of about 96% to a mean of about 100% of aliskiren hemi-fumarate, is released wherein the solid oral dosage form also comprises the following excipients in an amount by mg per unit dosage form of about 214 mg microcrystalline cellulose as filler, about 24.0 mg PVP K 30 as binder, about 96.4 mg crospovidone as disintegrant, about 3.6 mg colloidal silicon dioxide as glidant, and about 10.0 mg magnesium stearate as lubricant.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Mallinckrodt
Chubb
Deloitte
Daiichi Sankyo
Boehringer Ingelheim
Julphar
Johnson and Johnson
Fuji
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot